Pretargeted radioimmunotherapy of colorectal cancer metastases: Models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 12, 2011, Pages 2153-2164

  Frampas, Eric ^a   Maurel, Catherine ^a   Saëc, Patricia Remaud Le ^a   Mauxion, Thibault ^a   Faivre Chauvet, Alain ^a   Davodeau, François ^a   Goldenberg, David M ^b,c   Bardiès, Manuel ^a   Barbet, Jacques ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b IMMUNOMEDICS INC   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Bispecific antibody; Colonic cancer; Mice; Pretargeting; Radioimmunotherapy; Radionuclide

Indexed keywords

BISMUTH 213; BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; HAPTEN ANTIBODY; IODINE 131; LUTETIUM 177; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BONE MARROW; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIVER METASTASIS; MOUSE; NONHUMAN; PRETARGETED RADIOIMMUNOTHERAPY; RADIATION ABSORPTION; RADIATION DOSE; RADIOIMMUNOTHERAPY; RELATIVE BIOLOGIC EFFECTIVENESS;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; HUMANS; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; RADIOIMMUNOTHERAPY; RADIOISOTOPES; TISSUE DISTRIBUTION;

EID: 84856212043     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1903-0     Document Type: Article

References (41)

1. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000;321:531-5.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. (Pubitemid 38702844)
3. Zhu H, Baxter LT, Jain RK. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med 1997;38:731-41. (Pubitemid 27204049)
4. Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, et al. High-dose therapy with 90yttriumlabeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res 2000;6(8):3095-102. (Pubitemid 30637733)
5. Goldenberg DM, Chatal JF, Barbet J, Boerman O, Sharkey RM. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther 2007;2(1):19-31. (Pubitemid 46970909)
6. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1358-66. (Pubitemid 19190299)
7. Le Doussal JM, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J. Targeting of indium-111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res 1990;50:3445-52. (Pubitemid 20190158)
8. Gautherot E, Le Doussal JM, Bouhou J, Manetti C, Martin M, Rouvier E, et al. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J Nucl Med 1998;39(11):1937-43. (Pubitemid 28518896)
9. Sharkey RM, Karacay H, Vallabhajosula S, McBride WJ, Rossi EA, Chang CH, et al. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology 2008;246:497-507.
10. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A 2006;103(18):6841-6.
11. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH. Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008;49:158-63.
12. Bitar A, Lisbona A, Thedrez P, Sai Maurel C, Le Forestier D, Barbet J, et al. A voxel-based mouse for internal dose calculations using Monte Carlo simulations (MNCP). Phys Med Biol 2007;52:1013-25. (Pubitemid 46646414)
13. McBride WJ, Zanzonico P, Sharkey RM, Norén C, Karacay H, Rossi EA, et al. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med 2006;47:1678-88. (Pubitemid 47545036)
14. Frampas E, Saï-Maurel C, Thedrez P, Remaud-Le Saëc P, Faivre-Chauvet A, Barbet J. The intraportal injection model for liver metastasis: advantages of associated bioluminescence to assess tumor growth and influences on tumor uptake of radiolabeled anticarcinoembryonic antigen antibody. Nucl Med Commun 2011;32(2):147-53.
15. Schoffelen R, van der Graaf WTA, Franssen G, Sharkey RM, Goldenberg DM, McBride WJ, et al. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med 2010;51:1780-7.
16. Karacay H, Sharkey RM, Gold DV, Ragland DR, McBride WJ, Rossi EA, et al. Pretargeted radioimunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med 2009;50:2008-16.
17. Bitar A, Lisbona A, Bardiès M. S-factor calculations for mouse models using Monte-Carlo simulations. Q J Nucl Med Mol Imaging 2007;51:343-51. (Pubitemid 350267705)
18. Bardiès M, Chatal JF. Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres. Phys Med Biol 1994;39(6):961-81.
19. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the secondgeneration personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46(6):1023-7. (Pubitemid 43733519)
20. MIRD radionuclide data and decay schemes, 2nd ed. Eckerman KF, Endo A, editors. Reston: The Society of Nuclear Medicine; 2008.
21. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy. J Nucl Med 2010;51:311-28.
22. Elgqvist J, Bernhardt P, Hultborn R, Jensen H, Karlsson B, Lindegren S, et al. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice. J Nucl Med 2005;46:464-71. (Pubitemid 43093156)
23. Bäck T, Haraldsson B, Hultborn R, Jensen H, Johansson ME, Lindegren S, et al. Glomerular filtration rate after alpharadioimmunotherapy with 211At-MX35-F (ab') 2: a long-term study of renal function in nude mise. Cancer Biother Radiopharm 2009;24(6):649-58.
24. Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003;63:354-63. (Pubitemid 36152493)
25. Karacay H, Sharkey RM, McBride WJ, Griffiths GL, Qu Z, Chang K, et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen. Bioconjug Chem 2002;13(5):1054-70.
26. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 2008;68(13):5282-90.
27. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med 2010;40:190-203.
28. Cardillo TM, Karacay H, Goldenberg DM, Yeldell D, Chang CH, Modrak DE, et al. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy. Clin Cancer Res 2004;10:3552-61. (Pubitemid 38685466)
29. Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 2005;11(19 Suppl):7109s-21s. (Pubitemid 41428712)
30. Breeman WAP, de Jong M, Visser TJ, Erion JL, Krenning EP Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917-20. (Pubitemid 36734213)
31. Brechbiel MW. Targeted α-therapy: past, present, future? Dalton Trans 2007;43:4918-28.
32. Chérel M, Davodeau F, Kraeber-Bodéré F, Chatal JF. Current status and perspectives in alpha radioimmunotherapy. Q J Nucl Med Mol Imaging 2006;50:322-9. (Pubitemid 46157613)
33. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34(4):689-94. (Pubitemid 23115673)
34. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti- carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 1997;38:858-70. (Pubitemid 27251973)
35. Thames HD, Hendry JH. Radiation-induced injury to tissues. In: Thames HD, editor. Fractionation in radiotherapy. London: Taylor and Francis; 1987. p. 1-21.
36. Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, et al. High-linear energy transfer (LET) α versus low-LET β emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi-versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res 1999;59:2635-43. (Pubitemid 29269111)
37. Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, et al. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with β-, Auger/conversion electron-, or α-emitters. Clin Cancer Res 1999;5:3031s-43s. (Pubitemid 29493892)
38. Karagiannis TC. Comparison of different classes of radionuclides for potential use in radioimmunotherapy. Hell J Nucl Med 2007;10(2):82-8. (Pubitemid 47342270)
39. Sharkey RM, Primus FJ, Goldenberg DM. Antibody protein dose and radioimmunodetection of GW-39 human colon tumor xenografts. Int J Cancer 1987;39:611-7. (Pubitemid 17084734)
40. Vogel CA, Galmiche MC, Westermann P, Sun LQ, Pèlegrin A, Folli S, et al. Carcinoembryonic antigen expression, antibody localisation and immunophotodetection of human colon cancer liver metastases in nude mice: a model for radioimmunotherapy. Int J Cancer 1996;67:294-302. (Pubitemid 26274164)
41. Fidarova EF, El-Emir E, Boxer GM, Qureshi U, Dearling JLJ, Robson MP, et al. Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for radioimmunotherapy. Clin Cancer Res 2008;14(9):2639-46.